Cargando…
P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA.
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431084/ http://dx.doi.org/10.1097/01.HS9.0000971656.75971.7b |
| _version_ | 1785091115816321024 |
|---|---|
| author | Zhi-Ming, LI Yang, Hang Yin, Yanxue LI, Yajun Zhou, Shiyong Sun, Peng Wang, Yu Zhang, Lu Zhou, Hui Zhang, Huilai |
| author_facet | Zhi-Ming, LI Yang, Hang Yin, Yanxue LI, Yajun Zhou, Shiyong Sun, Peng Wang, Yu Zhang, Lu Zhou, Hui Zhang, Huilai |
| author_sort | Zhi-Ming, LI |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431084 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104310842023-08-17 P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. Zhi-Ming, LI Yang, Hang Yin, Yanxue LI, Yajun Zhou, Shiyong Sun, Peng Wang, Yu Zhang, Lu Zhou, Hui Zhang, Huilai Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431084/ http://dx.doi.org/10.1097/01.HS9.0000971656.75971.7b Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Zhi-Ming, LI Yang, Hang Yin, Yanxue LI, Yajun Zhou, Shiyong Sun, Peng Wang, Yu Zhang, Lu Zhou, Hui Zhang, Huilai P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. |
| title | P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. |
| title_full | P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. |
| title_fullStr | P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. |
| title_full_unstemmed | P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. |
| title_short | P1190: EFFICACY AND SAFETY OF SELINEXOR COMBINING WITH R-CHOP IN THE TREATMENT OF NEWLY DIAGNOSED HIGH RISK (IPI 3-5) GCB SUBTYPE DLBCL PATIENTS: A MULTICENTER RETROSPECTIVE REAL-WORLD STUDY FROM CHINA. |
| title_sort | p1190: efficacy and safety of selinexor combining with r-chop in the treatment of newly diagnosed high risk (ipi 3-5) gcb subtype dlbcl patients: a multicenter retrospective real-world study from china. |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431084/ http://dx.doi.org/10.1097/01.HS9.0000971656.75971.7b |
| work_keys_str_mv | AT zhimingli p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT yanghang p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT yinyanxue p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT liyajun p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT zhoushiyong p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT sunpeng p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT wangyu p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT zhanglu p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT zhouhui p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina AT zhanghuilai p1190efficacyandsafetyofselinexorcombiningwithrchopinthetreatmentofnewlydiagnosedhighriskipi35gcbsubtypedlbclpatientsamulticenterretrospectiverealworldstudyfromchina |